← Evidence map

ArticleNature biotechnology2016

Alnylam terminates revusiran program, stock plunges.

Ken GarberPubMed ↗Publisher ↗

No numbers read from the abstract.

30 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27926717